ARS Pharmaceuticals, Inc. (SPRY) Reports In-Line Q2 EPS

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) reported Q2 EPS of ($0.46), in-line with the analyst estimate of ($0.46). Revenue for the quarter came in at $15.72 million versus the consensus estimate of $13.77 million.

For earnings history and earnings-related data on ARS Pharmaceuticals, Inc. (SPRY) click here.

You May Also Be Interested In

• Kotak Starts Aequs Ltd (AEQUS:IN) at Reduce (3)
• BNP Paribas Exane Starts NHPC Ltd (NHPC:IN) at Underperform
• Methode Electronics (MEI) Tops Q1 EPS by 2c; offers guidance